23093-74-5

Usage

Uses

Used in Pharmaceutical Industry:
Bunitrolol HCL is used as an antihypertensive agent for the treatment of hypertension, helping to manage high blood pressure by reducing the force and rate of heart contractions, which in turn decreases cardiac output and blood pressure.
BUNITROLOL HCL is used as an anti-anginal agent for the treatment of angina, providing relief from chest pain and pressure caused by insufficient blood flow to the heart muscle. It achieves this by reducing the heart's oxygen demand and workload.
Additionally, due to its non-selective nature, Bunitrolol HCL may have other applications in the medical field where beta-blockers are beneficial, such as in the management of certain cardiac arrhythmias, heart failure, and prevention of migraines, though specific uses would depend on clinical indications and patient needs.

InChI:InChI=1/C14H20N2O2.ClH/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15;/h4-7,12,16-17H,9-10H2,1-3H3;1H

Downstream Products

• 125721-13-3 2-{3-Hydroxyimino-2-[(Z)-hydroxyimino]-propoxy}-benzonitrile 
• 125721-04-2 2-{3-Hydroxyimino-2-[(E)-hydroxyimino]-propoxy}-benzonitrile 
• 125720-92-5 2-{3-tert-Butylamino-2-[(E)-hydroxyimino]-propoxy}-benzonitrile 
• 125720-91-4 2-{3-tert-Butylamino-2-[(Z)-hydroxyimino]-propoxy}-benzonitrile 
• 46905-83-3 (S)-1-(2-cyanophenoxy)-2-hydroxy-3-tert-butylamino-propane 
• 46905-83-3 (R)-1-(2-cyanophenoxy)-2-hydroxy-3-tert-butylamino-propane 

Relevant academic research and scientific papers

1-Phenoxy-2-hydroxy-3-tert.-butylamino propane antiarrhythmic compounds

A compound selected from the group consisting of racemates of 1-phenoxy-2-hydroxy-3-tert.-butylamino propanes of the formula STR1 wherein R is selected from the group consisting of alkynyloxy of 2 to 4 carbon atoms, and R1 is selected from the group consisting of hydrogen, halogen and alkoxy of 1 to 4 carbon atoms, their optically active isomers and their non-toxic, pharmaceutically acceptable acid addition salts of said racemates and said optically active isomers which compounds possess bradycardia activity and isoproterenol antagonistic activity and also antiarrhythmic activity.

Therapeutic compositions and method

A composition having bradycardia and isoproterenol antagonistic activity comprising at least one compound selected from the group consisting of racemates of 1-phenoxy-2-hydroxy-3-tert.-butylamino propanes of the formula EQU1 wherein R is selected from the group consisting of --(CH2)x --CN where x is an integer from 0 to 3, COOH and COOR' where R' is alkyl of 1 to 4 carbon atoms; R1 is selected from the group consisting of hydrogen, alkoxy and alkylthio of 1 to 4 carbon atoms, --CN and alkenyl and alkynyl of 2 to 4 carbon atoms and R2 is selected from the group consisting of hydrogen, halogen and alkyl and alkoxy of 1 to 4 carbon atoms, their optically active isomers and their non-toxic, pharmaceutically acceptable acid addition salts of said racemates and said optically active isomers and a major amount of a pharmaceutical carrier and a method of producing bradycardia and suppressing tachycardia effects of N-isopropyl-noradrenaline in warm-blooded animals.